Enfusion logo

EnfusionNYSE: ENFN

Profile

Sector:

Technology

Country:

United States

IPO:

21 October 2021

Next earnings report:

08 August 2024

Last dividends:

N/A

Next dividends:

N/A
$806.06 M
-45%vs. 3y high
52%vs. sector
292.33
-10%vs. 3y high
97%vs. sector
-45%vs. 3y high
92%vs. sector
-69%vs. 3y high
68%vs. sector

Price

after hours | Fri, 05 Jul 2024 21:29:10 GMT
$8.77+$0.19(+2.21%)

Dividend

No data over the past 3 years
$48.05 M$50.05 M
$48.05 M-$539.00 K

Analysts recommendations

Institutional Ownership

ENFN Latest News

Enfusion: Expectations Of Faster Growth And Higher Margins Justify A Buy Rating
seekingalpha.com15 June 2024 Sentiment: -

Enfusion targets to grow its top line at a faster pace by optimizing its customer mix. Positive operating leverage and an increase in operating efficiency will support higher EBITDA margins for Enfusion. I expect ENFN to achieve revenue growth acceleration and profitability improvement in the future, and this supports a Buy rating.

Enfusion To Present at Upcoming Investor Events
businesswire.com29 May 2024 Sentiment: POSITIVE

NEW YORK & LONDON & HONG KONG--(BUSINESS WIRE)--Enfusion, Inc. ("Enfusion") (NYSE: ENFN), a leading provider of software-as-a-service (SaaS) solutions for investment managers, today announced that Enfusion's Chief Executive Officer, Oleg Movchan, and Chief Financial Officer, Brad Herring, and Chief Operating Officer, Neal Pawar, will participate at the following investor events: William Blair's 44th Annual Growth Stock Conference on Wednesday, June 5, 2024 Morgan Stanley US Financials, Payments.

Enfusion Announces Date of First Quarter 2024 Results
Business Wire18 April 2024 Sentiment: POSITIVE

Enfusion, Inc. (NYSE: ENFN), a top provider of SaaS solutions for investment managers, will release its Q1 2024 financial results before the U.S. markets open on May 9, 2024. Management will hold a conference call and webcast at 5:30 AM (PT) / 8:30 AM (ET) to discuss the results. To join the call, dial (888) 596-4144 with the conference ID number.

Enfusion: TAM Penetration Continues To Progress Well
Seeking Alpha31 March 2024 Sentiment: POSITIVE

ENFN reported solid Q4 earnings with accelerating revenue growth and a strong pipeline. The company is successfully penetrating the total addressable market (TAM) in the asset management industry. ENFN's focus on product innovation and total cost of ownership (TCO) advantage will drive future growth and close the valuation gap with peers.

Enfusion, Inc. (ENFN) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
Zacks Investment Research12 March 2024 Sentiment: NEUTRAL

The headline numbers for Enfusion, Inc. (ENFN) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Enfusion, Inc. (ENFN) Lags Q4 Earnings Estimates
Zacks Investment Research12 March 2024 Sentiment: NEUTRAL

Enfusion, Inc. (ENFN) came out with quarterly earnings of $0.04 per share, missing the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.03 per share a year ago.

Enfusion, Inc. (ENFN) Q4 2023 Earnings Call Transcript
Seeking Alpha12 March 2024 Sentiment: POSITIVE

Enfusion, Inc. (ENFN) Q4 2023 Earnings Call Transcript

Enfusion: Product Is Sticky And Industry Is Huge
Seeking Alpha18 January 2024 Sentiment: POSITIVE

I am recommending a buy rating as I see room for ENFN to grow and visible catalysts for growth acceleration. The company provides an end-to-end SaaS solution for investment managers, making it a sticky product with high pricing power. The industry is large and healthy, with ample opportunities for Enfusion to expand its market share.

Enfusion, Inc. (ENFN) Q3 2023 Earnings Call Transcript
Seeking Alpha11 November 2023 Sentiment: POSITIVE

Enfusion, Inc. (NYSE:ENFN ) Q3 2023 Results Conference Call November 7, 2023 8:30 AM ET Company Participants Ignatius Njoku - Head, IR Oleg Movchan - CEO Brad Herring - CFO Conference Call Participants Michael Infante - Morgan Stanley Faith Brunner - William Blair Elyse Kanner - JPMorgan Parker Lane - Stifel Crispin Love - Piper Sandler Callie Valenti - Goldman Sachs Natalie Howe - Bank of America Operator Good afternoon, ladies and gentlemen, and thank you for standing by. Welcome to Enfusion's Third Quarter 2023 Earnings Conference Call.

Enfusion: Still Bullish Considering Q3 EBITDA Beat
Seeking Alpha08 November 2023 Sentiment: POSITIVE

Enfusion's EBITDA expanded by +48% YoY in Q3 2023, which was +6% better than what the market had expected. ENFN's long-term prospects are favorable, taking into account the room for revenue growth and profit margin improvement. I retain a Buy rating for ENFN stock, in consideration of its good recent quarterly results and positive financial outlook.

  • 1(current)

What type of business is Enfusion?

Enfusion, Inc. provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. It provides portfolio management system, which generates a real-time investment book of record that consists of valuation and risk tools that allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and order and execution management system that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines. The company also offers accounting/general ledger system, a real-time accounting book of record for chief financial officers, chief operating officers, accountants, and operations teams; Enfusion analytics system, which enables CIOs, portfolio managers, traders, and analysts to analyze portfolios through time horizons and automate customized visualized reports for internal and external stakeholders; and technology-powered and managed services. Enfusion Inc. was incorporated in 2021 and is headquartered in Chicago, Illinois.

What sector is Enfusion in?

Enfusion is in the Technology sector

What industry is Enfusion in?

Enfusion is in the Software Application industry

What country is Enfusion from?

Enfusion is headquartered in United States

When did Enfusion go public?

Enfusion initial public offering (IPO) was on 21 October 2021

What is Enfusion website?

https://www.enfusion.com

Is Enfusion in the S&P 500?

No, Enfusion is not included in the S&P 500 index

Is Enfusion in the NASDAQ 100?

No, Enfusion is not included in the NASDAQ 100 index

Is Enfusion in the Dow Jones?

No, Enfusion is not included in the Dow Jones index

When does Enfusion report earnings?

The next expected earnings date for Enfusion is 08 August 2024